Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 9 for:    antroquinonol

A Trial of Antroquinonol in Patients With Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03622463
Recruitment Status : Completed
First Posted : August 9, 2018
Last Update Posted : August 29, 2019
Sponsor:
Information provided by (Responsible Party):
Golden Biotechnology Corporation

Brief Summary:
This is a multi-centers, phase IIa, double blind, randomized, placebo-controlled trial of Antroquinonol in patients with atopic dermatitis.Duration of treatment is 12 week in total. Study visits will occur every 4 weeks. AEs/SAEs, changes to concomitant medications will be noted, vital signs will be taken, and efficacy evaluations will be performed as well. The last estimation of variable scores will occur for all subjects.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Antroquinonol Other: Placebo Phase 2

Detailed Description:
This is a multi-centers, phase IIa, double blind, randomized, placebo-controlled trial of Antroquinonol in patients with atopic dermatitis.Duration of treatment is 12 week in total. Study visits will occur every 4 weeks. During these visits study drug will be administered at the site, new AEs/SAEs as well as follow-up for AEs and SAEs that have not been resolved will be recorded, changes to concomitant medications will be noted, vital signs will be taken, and efficacy evaluations will be performed as well. The study includes collection of cytokines samples. The end-of-treatment visit and the last estimation of variable scores will occur at week 13 (visit 5) for all subjects. The final visit will be at week 15 (visit 6). Subjects will be encouraged to complete all planned visits regardless of their adherence to study drug administration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This is a multi-centers, phase IIa, double blind, randomized, placebo-controlled trial of Antroquinonol in patients with atopic dermatitis. Subjects with diagnosis of atopic dermatitis, using the Hanifin and Rajka Diagnostic Criteria, who meet inclusion/exclusion criteria will be randomized into 3 groups:

  1. Antroquinonol 100 mg PO QD
  2. Antroquinonol 50 mg PO QD
  3. Placebo
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-controlled Trial of Antroquinonol in Patients With Atopic Dermatitis
Actual Study Start Date : July 17, 2018
Actual Primary Completion Date : July 9, 2019
Actual Study Completion Date : July 9, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: Antroquinonol 100 mg PO QD
Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol,once a day.
Drug: Antroquinonol
Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
Other Name: Hocena

Experimental: Antroquinonol 50 mg PO QD
Antroquinonol (Hocena) 50mg/capsule. 1 capsules antroquinonol and 1 capsule placebo, once a day.
Drug: Antroquinonol
Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
Other Name: Hocena

Other: Placebo
The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects

Placebo Comparator: Placebo
Placebo capsule, 2 capsules placebo, once a day
Other: Placebo
The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects




Primary Outcome Measures :
  1. EASI value [ Time Frame: 12 weeks ]

    Eczema Area and Severity Index: Each body region has potentially 100% involvement. Using the table below, give each respective body region a score of between 0 and 6 based on the percentage involvement. Precise measurements are not required.

    % involvement 0 1-9% 10 - 29% 30 - 49% 50 - 69% 70 - 89% 90 - 100% Region score 0 1 2 3 4 5 6



Secondary Outcome Measures :
  1. SCORAD [ Time Frame: 12 weeks ]
    Scoring Atopic Dermatitis which ranges from 0 to 103, with higher scores indicating more severe disease



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients between the ages of 20 and 65 years who had moderate-to-severe atopic dermatitis (using the Hanifin and Rajka Diagnostic Criteria)
  • Patients with body weight ≥ 25 kg and ≤ 120 kg, singing informed consent
  • To be eligible to participate, patients were required to havea.

    1. score of at least 5 on the Eczema Area and Severity Index (EASI), which rangesfrom 0 to 72, with higher scores indicating worse disease severity;
    2. a score for pruritus of at least 30 mm on a visual-analogue scale, which ranges from 0 (no itch) to 100 mm (worst itch imaginable);
    3. a score of at least 2 on the static Investigator's Global Assessment (sIGA), which ranges from 0 (clear) to 4 ( severe disease).
    4. BSA affected or PSAI ≥ 5%

Exclusion Criteria:

  1. Patients with active dermatologic diseases concomitant with atopic dermatitis.
  2. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study
  3. Subjects with defective epidermal barrier(e.g Netherton's syndrome)
  4. Any subject who is immunocompromised or has a history of malignant disease. This information will be gathered verbally from the patient while taking a medical history from the patient, and will not involve further testing such as an HIV test.
  5. Subjects with a history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol
  6. Any noticeable breaks or cracks in the skin on either arm, including severely excoriated skin or skin with open or weeping wounds suggestive of an active infection or increased susceptibility to infection.
  7. Ongoing participation in another investigational trial
  8. Use of any oral or topical antibiotic for up to four weeks prior to the reatment visit or active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy
  9. Use of any systemic immunosuppressive therapy (e.g. CsA, MTX, etc.) within four weeks of the Treatment visit.
  10. Participant who has a condition or is in a situation that, in the investigator's opinion, may put the patient at significant risk, or may significantly interfere with the patient's participation in the study.
  11. Subjects with prosthetic heart valves, pacemakers, intravascular catheters, or other foreign or prosthetic devices.
  12. History of food or drug related severe anaphylactoid or anaphylactic reaction(s)
  13. Pregnancy or breast feeding
  14. History or presence of epilepsy, significant neurological disorders, cerebrovascular attack or ischemia
  15. History or presence of myocardial infarction or cardiac arrhythmia under drug therapy
  16. Patients who are unable to complete questionnaires on paper.
  17. Clinically significant laboratory abnormalities.
  18. History of malignancy of any organ system, treated or untreated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03622463


Locations
Layout table for location information
Taiwan
Chung Shan Medical University Hospital
Taichung, Taiwan
Sponsors and Collaborators
Golden Biotechnology Corporation
Investigators
Layout table for investigator information
Principal Investigator: Cheng-Chung Wei, MD Chung Shan Medical University

Layout table for additonal information
Responsible Party: Golden Biotechnology Corporation
ClinicalTrials.gov Identifier: NCT03622463    
Other Study ID Numbers: GHADERM-2-001
First Posted: August 9, 2018    Key Record Dates
Last Update Posted: August 29, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Golden Biotechnology Corporation:
Antroquinonol
Hocena
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Ubiquinone
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs